Cara Therapeutics licenses worldwide rights to Korsuva to Vifor Fresenius Medical Care Renal Pharma Ltd except for USA, Japan and South Korea.

Cara Therapeutics, Inc. a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors,has announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize Korsuva (CR 845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP), a joint company of Vifor Pharma Group and Fresenius Medical Care that specializes in treatments for CKD. The FDA granted Breakthrough Therapy Designation to Korsuva injection for this indication, for which there are currently no approved therapies in the U.S. or EU.